proCardio 2026

Dr. Aleksandra Lezaja (Roche Diagnostics CH)

I think this was a really exceptional proCardio, we had a lot of firsts. It is the first time we had over 270 participants, it is the first time that we brought proCardio here to Roche, to Basel, to our home. It is also the first time that we had Pharma and Dia together, which is also reflected in our agenda.

Dr. Juwairia Al-Ali, Rashid Hospital Dubai (UAE)

I like the fact that we could talk among each other and talk with the experts about all these issues that we usually talk about only amongst our own specialties. That was really, really enriching and I thought that we came up with lots of new ideas that we want to implement in our own countries. 

Dr. Manu Chakravarthy (Roche Pharma US)

All in all I think it is a very exciting forum, we are learning a lot and I think this is going to make a big impact for our patients, both as we think about how to bring under OneRoche both the Diagnostic and the Pharma divisions. 

Dr. Antonio Bunõ (Spain)

I really value to have the opportunity to share between clinicians and laboratorians our different points of view, the clinical needs, the laboratory point of view, putting together all of this knowledge and sharing all our expertise, combined to provide better patient care.

Prof. Dmytro Lashkul (Ukraine)

The skills and the knowledge which I bring from this event, I bring to my country to improve the organization of the healthcare system.

Prof. James Januzzi (USA)

The highlights for me have been the ongoing evolution of the understanding of cardiovascular disease, relative to early stage diagnostics all the way to therapeutics. So on Day 1 and Day 2 of  proCardio you can really see this evolution. It used to be a meeting talking about biomarkers, now it is really a discussion about the holistic care of patients. Prevention of heart disease, prevention of heart failure, treatment of established disease, better management of, for example, the cardio-kidney-metabolic syndrome. Really critical steps forward to improve the care of our patients. 

Prof. Michael Gibson (USA)

I think patient empowerment is here to stay. We are going to be bringing the trials, the therapies, the markers, everything into the home to accelerate care and lower the barriers. 

Prof. Mariana Fontana (UK)

It is an incredible event. Incredible faculty, medium size meeting, so it is not one of those meetings where you get lost and you have really the opportunity to interact with the highest level of faculty and people involved in the biomarker development. 

Dr. Pam Taub (USA)

So, we are in a revolution right now with cardio-metabolic disease where we are starting to really think about everything holistically. 

Dr. Victor Jeger (Roche Diagnostics)

We have learnt a lot. I really value the insights from early development, early research, to guideline implementation large trials, and now the last session I just came from, on Policy. 

Prof. Lori Daniels (USA)

People leave here energized and ready to take this into action and it is because of you bringing everyone together in a thoughtful way with such great science backing it up. 

Dr. Aleksandra Lezaja (Roche Diagnostics CH)

And if you think about it, this year, we had cardiologists, interventional cardiologists, epidemiologists, endocrinologists, so completely different perspectives to have a full spectrum of care.